| Peer-Reviewed

Anticoagulation of Behcet’s Disease with Thrombosis: A Series of 28 Cases in a Tertiary Care Centre in Saudi Arabia

Received: 30 March 2017     Accepted: 24 April 2017     Published: 15 June 2017
Views:       Downloads:
Abstract

Behcet’s disease (BD) is a multisystemic inflammatory disorder of unknown etiology. There is few data about BD in Saudi Arabia. This is a retrospective chart review study of 28 patients of BD with thrombosis on long term anticoagulation. A total of 28 BD patients, their mean age was 43.8 (25-60) years. The mean age of first thrombosis was 29.2 (14-42) years. Provoked thrombosis was reported in 17.86% of the patients. The commonest site of thrombosis was superficial femoral vein 35.71%, followed by popliteal vein 32.14%, pulmonary embolism (PE) 32.14%. Anti B2 glycoprotein 1 antibodies was identified in 31.82% of patients, Anti cardiolipin Antibodies in 22.73%, Leiden factor V in 18.18%. Activity of the disease during thrombosis was recognized as oral ulcer 44.44%, genital ulcer 33.33%, Human leukocyte antigen-B (HLAB) was 32.14%. Thrombosis while patient on anticoagulation was reported in 32.14% of patients. Bleeding was reported in 14.29% of patients, common site of bleeding was gastrointestinal bleeding. Survival rate was 78.57% and 2 patients were died (7.14%) due to malignancy. Conclusion: Thrombosis in BD patients is male predominance, more in venous, has low mortality, frequency of thrombosis is more in the presence of thrombophilia and active BD. The prevalence of thrombophilia among BD patients is high. The presence of thrombophilia still affect the physician decision regarding the initiation and duration of anticoagulation in BD. The incidence of bleeding with long term anticoagulation is low. Further research is needed to find out the prevalence of cancer among BD in Saudis.

Published in American Journal of Internal Medicine (Volume 5, Issue 4)
DOI 10.11648/j.ajim.20170504.12
Page(s) 57-60
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2017. Published by Science Publishing Group

Keywords

Behcet’s Disease, Anticoagulation, Trombosis, Thrombophilia

References
[1] Mizuki N, Meguro A, Tohnai I, et al.: Association of major histocompatibility complex class I chain-related gene A and HLA-B alleles with Behcet’s disease in Turkey. Jpn J Ophthalmol 2007; 51: 431–436.
[2] Ando H, Mizuki. Identification of a novel HLA-B allele (B*4202) in a Saudi Arabian family with Behcet's disease. Tissue Antigens. 1997; 49 (5): 526-8. PMID: 9174150.
[3] Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Behçet syndrome. Am J Med 2004; 117: 867.
[4] Tayer-Shifman OE. Major vessel thrombosis in Behçet's disease: the dilemma of anticoagulant therapy - the approach of rheumatologists from different countries. Clin Exp Rheumatol. 2012 Sep-Oct; 30 (5): 735-40.
[5] Al-Dalaan AN. Behçet's disease in Saudi Arabia. J Rheumatol. 1994 Apr; 21 (4): 658-61.
[6] Yazici Y, Yurdakul S, Yazici H. Behçet’s syndrome. Curr Rheumatol Rep 2010; 12: 429-35.
[7] Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med 1999; 341: 1284-91.
[8] Xiuhua Wu,, Guohua Li,, Xinxiang Huang,, Li Wang,, Wanli Liu, Behçet's Disease Complicated with Thrombosis-A Report of 93 Chinese Cases. Medicine (Baltimore). 2014 Dec; 93 (28): e263.
[9] Erkan Alpsoy. New Evidence-Based Treatment Approach in Behçet's Disease. Pathology Research International. Volume 2012 (2012), Article ID 871019, 11 pages.
[10] Sarr SA, Superior vena cava syndrome revealing a Behçet's disease. Thromb J. 2015 Jan 31; 13: 7.
[11] Saadoun D, Wechsler B. Behcet’s disease. Orphanet J Rare Dis. 2012; 7: 20.
[12] Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behcet’s disease: an update. Curr Opin Rheumatol. 2011; 23: 24–31.
[13] R. J. Ames, A. Steuer, A. Pap, and A. M. Denman, “Thrombosis in Behcet’s disease: a retrospective survey from a single UK centre,” Rheumatology; 40 (6): 652– 655, 2001.
[14] Emire Seyahi, MD, Melike Melikoglu, Canan Akman, Vedat Hamuryudan, Harun Ozer, Gulen Hatemi, Sebahattin Yurdakul, Hasan Tuzun, Buge Oz, and Hasan Yazici, “Pulmonary Artery Involvement and Associated Lung Disease in Behçet Disease”, Medicine 2012; 91: 35-48.
[15] Micaela La Regina, Armen Yuri Gasparyan, Behçet’s Disease as a Model of Venous Thrombosis. Open Cardiovasc Med J. 2010; 4: 71–77.
[16] NŞ, Salgür F, Cansu DÜ, et al. Combined thrombophilic factors increase the risk of recurrent thrombotic events in Behcet's disease. Clin Rheumatol 2010; 29: 1367–1372.
[17] Puja Mehta, Thrombosis and Behçet’s syndrome in non-endemic regions. Is there a way around? Rheumatology (2010) 49 (11): 2003-2004.
[18] Alibaz-Oner F, et al. Study: No benefit from anticoagulant use in Behçet’s disease. Medicine. 2015.
[19] Giacomo Emmi, Elena Silvestri, Danilo Squatrito. Thrombosis in vasculitis: from pathogenesis to treatment. Thromb J. 2015; 13: 15.
[20] Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60.
[21] Saadoun D, Wechsler B, Desseaux K, et al. Mortality in Behçet's disease. Arthritis Rheum 2010; 62: 2806.
[22] Kaklamani VG, Tzonou A, Kaklamanis PG. Behçet's disease associated with malignancies. Report of two cases and review of the literature. Clin Exp Rheumatol. 2005 Jul-Aug; 23 (4 Suppl 38): S35-41.
[23] Lin Y, Li G, Zheng W, Tian X, Zhang F. Behcet's disease associated with malignancy: a report of 41 Chinese cases. Int J Rheum Dis. 2014 May; 17 (4): 459-65.
Cite This Article
  • APA Style

    Muneerah Albugami, Ahmed Al Shaikh, Abdulaziz Alrashed, Hanan Al Hamzi, Alanoud Khuthaila, et al. (2017). Anticoagulation of Behcet’s Disease with Thrombosis: A Series of 28 Cases in a Tertiary Care Centre in Saudi Arabia. American Journal of Internal Medicine, 5(4), 57-60. https://doi.org/10.11648/j.ajim.20170504.12

    Copy | Download

    ACS Style

    Muneerah Albugami; Ahmed Al Shaikh; Abdulaziz Alrashed; Hanan Al Hamzi; Alanoud Khuthaila, et al. Anticoagulation of Behcet’s Disease with Thrombosis: A Series of 28 Cases in a Tertiary Care Centre in Saudi Arabia. Am. J. Intern. Med. 2017, 5(4), 57-60. doi: 10.11648/j.ajim.20170504.12

    Copy | Download

    AMA Style

    Muneerah Albugami, Ahmed Al Shaikh, Abdulaziz Alrashed, Hanan Al Hamzi, Alanoud Khuthaila, et al. Anticoagulation of Behcet’s Disease with Thrombosis: A Series of 28 Cases in a Tertiary Care Centre in Saudi Arabia. Am J Intern Med. 2017;5(4):57-60. doi: 10.11648/j.ajim.20170504.12

    Copy | Download

  • @article{10.11648/j.ajim.20170504.12,
      author = {Muneerah Albugami and Ahmed Al Shaikh and Abdulaziz Alrashed and Hanan Al Hamzi and Alanoud Khuthaila and Abdelazeim Elamin and Mumin Siddiquee and Usamah El Alem and Lama Amer and Yasmin Altwaijri},
      title = {Anticoagulation of Behcet’s Disease with Thrombosis: A Series of 28 Cases in a Tertiary Care Centre in Saudi Arabia},
      journal = {American Journal of Internal Medicine},
      volume = {5},
      number = {4},
      pages = {57-60},
      doi = {10.11648/j.ajim.20170504.12},
      url = {https://doi.org/10.11648/j.ajim.20170504.12},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20170504.12},
      abstract = {Behcet’s disease (BD) is a multisystemic inflammatory disorder of unknown etiology. There is few data about BD in Saudi Arabia. This is a retrospective chart review study of 28 patients of BD with thrombosis on long term anticoagulation. A total of 28 BD patients, their mean age was 43.8 (25-60) years. The mean age of first thrombosis was 29.2 (14-42) years. Provoked thrombosis was reported in 17.86% of the patients. The commonest site of thrombosis was superficial femoral vein 35.71%, followed by popliteal vein 32.14%, pulmonary embolism (PE) 32.14%. Anti B2 glycoprotein 1 antibodies was identified in 31.82% of patients, Anti cardiolipin Antibodies in 22.73%, Leiden factor V in 18.18%. Activity of the disease during thrombosis was recognized as oral ulcer 44.44%, genital ulcer 33.33%, Human leukocyte antigen-B (HLAB) was 32.14%. Thrombosis while patient on anticoagulation was reported in 32.14% of patients. Bleeding was reported in 14.29% of patients, common site of bleeding was gastrointestinal bleeding. Survival rate was 78.57% and 2 patients were died (7.14%) due to malignancy. Conclusion: Thrombosis in BD patients is male predominance, more in venous, has low mortality, frequency of thrombosis is more in the presence of thrombophilia and active BD. The prevalence of thrombophilia among BD patients is high. The presence of thrombophilia still affect the physician decision regarding the initiation and duration of anticoagulation in BD. The incidence of bleeding with long term anticoagulation is low. Further research is needed to find out the prevalence of cancer among BD in Saudis.},
     year = {2017}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Anticoagulation of Behcet’s Disease with Thrombosis: A Series of 28 Cases in a Tertiary Care Centre in Saudi Arabia
    AU  - Muneerah Albugami
    AU  - Ahmed Al Shaikh
    AU  - Abdulaziz Alrashed
    AU  - Hanan Al Hamzi
    AU  - Alanoud Khuthaila
    AU  - Abdelazeim Elamin
    AU  - Mumin Siddiquee
    AU  - Usamah El Alem
    AU  - Lama Amer
    AU  - Yasmin Altwaijri
    Y1  - 2017/06/15
    PY  - 2017
    N1  - https://doi.org/10.11648/j.ajim.20170504.12
    DO  - 10.11648/j.ajim.20170504.12
    T2  - American Journal of Internal Medicine
    JF  - American Journal of Internal Medicine
    JO  - American Journal of Internal Medicine
    SP  - 57
    EP  - 60
    PB  - Science Publishing Group
    SN  - 2330-4324
    UR  - https://doi.org/10.11648/j.ajim.20170504.12
    AB  - Behcet’s disease (BD) is a multisystemic inflammatory disorder of unknown etiology. There is few data about BD in Saudi Arabia. This is a retrospective chart review study of 28 patients of BD with thrombosis on long term anticoagulation. A total of 28 BD patients, their mean age was 43.8 (25-60) years. The mean age of first thrombosis was 29.2 (14-42) years. Provoked thrombosis was reported in 17.86% of the patients. The commonest site of thrombosis was superficial femoral vein 35.71%, followed by popliteal vein 32.14%, pulmonary embolism (PE) 32.14%. Anti B2 glycoprotein 1 antibodies was identified in 31.82% of patients, Anti cardiolipin Antibodies in 22.73%, Leiden factor V in 18.18%. Activity of the disease during thrombosis was recognized as oral ulcer 44.44%, genital ulcer 33.33%, Human leukocyte antigen-B (HLAB) was 32.14%. Thrombosis while patient on anticoagulation was reported in 32.14% of patients. Bleeding was reported in 14.29% of patients, common site of bleeding was gastrointestinal bleeding. Survival rate was 78.57% and 2 patients were died (7.14%) due to malignancy. Conclusion: Thrombosis in BD patients is male predominance, more in venous, has low mortality, frequency of thrombosis is more in the presence of thrombophilia and active BD. The prevalence of thrombophilia among BD patients is high. The presence of thrombophilia still affect the physician decision regarding the initiation and duration of anticoagulation in BD. The incidence of bleeding with long term anticoagulation is low. Further research is needed to find out the prevalence of cancer among BD in Saudis.
    VL  - 5
    IS  - 4
    ER  - 

    Copy | Download

Author Information
  • Medicine Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

  • Medicine Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

  • Medicine Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

  • Medicine Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

  • Research Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

  • Medicine Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

  • Medicine Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

  • Medicine Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

  • Medicine Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

  • Research Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

  • Sections